Cover Image
市場調查報告書

全球醫藥基因學市場分析:打入經營者 (診斷檢驗·醫藥品)·疾病區分 (癌症·心血管)·各地區的估計·預測 (2016-2022年)

Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others) and Geography - Estimation & Forecast 2016-2022

出版商 BIS Research 商品編碼 355762
出版日期 內容資訊 英文 322 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球醫藥基因學市場分析:打入經營者 (診斷檢驗·醫藥品)·疾病區分 (癌症·心血管)·各地區的估計·預測 (2016-2022年) Global Pharmacogenomics (PGx) Market Analysis: Focus on Ecosystem Players (Diagnostic Test, Pharmaceutical & Others), Therapeutic Applications (Oncology, Cardiovascular & Others) and Geography - Estimation & Forecast 2016-2022
出版日期: 2016年04月04日 內容資訊: 英文 322 Pages
簡介

次世代定序和高通量篩檢,數位PCR等新醫療技術迅速發展和創新,建立了醫藥基因學市場成長的強力基礎。雖然醫藥基因學尚不能稱作是近代化的市場,但由於精密醫療和標靶治療的需求擴大,藥物有害反應的數量擴大等要素,在過去數年仍寫下大幅成長的記錄。

本報告提供全球醫藥基因學的市場調查,提供您醫藥基因學定義和概要,產業結構與價值鏈,相關法律·規格·認證,企業及企業間的配合措施·策略,技術區分·企業區分·疾病各種類趨勢與市場規模之變化與預測,地區分析,並彙整主要企業的簡介等資訊。

第1章 報告概要

第2章 摘要整理

第3章 市場概要

  • 簡介
  • 醫藥基因學 (PGX):作用機制
  • PGX的搭配診斷所扮演的角色
  • PGX的生物標記所扮演的角色
  • PGX的分子診斷所扮演的角色
  • PGX的優點
  • 最終用途
  • 市場動態
    • 成長推進因素
    • 課題
    • 市場機會

第4章 競爭分析

  • 市場主要發展·策略
    • 主要企業的競爭環境
    • 聯盟·合資企業·合作
    • 產品的開發·投入
    • 專利·授權·認證·核准
    • M&A
    • 產業契約·產業的擴張
    • 其他
  • 波特的五力分析

第5章 產業分析

  • 專利分析
  • 法律規章·財團·認證·規格
  • 價值鏈分析

第6章 全球醫藥基因學市場:各技術

  • 市場分析:各技術
  • 微陣列
    • 簡介
    • 各種類型·用途·主要企業
    • 市場動態·近幾年的發展
  • 定序
    • 簡介
    • 市場動態·用途·主要企業
    • 各種類型
      • Sanger測序
      • 焦磷酸測序
      • NGS
  • PCR
    • 簡介
    • 各種類型
    • 市場動態·用途·主要企業
  • 其他
    • 質譜分析
    • 電泳

第7章 全球醫藥基因學市場:生態系統企業別

  • PGX生態系統企業:概要
  • 市場分析:生態系統企業別
    • 市場分析·統計
  • 診斷檢驗企業
    • 簡介
    • 市場統計
    • 成長推進因素·課題
    • 近幾年主要的發展
    • 主要企業
  • 醫藥品企業
    • 簡介
    • 市場統計
    • 藥物開發過程
    • 醫藥品企業所扮演的角色和醫藥品範例
    • 醫藥品企業:成長推進因素·課題
    • 近幾年主要的發展
    • 主要企業
  • 服務供應商
    • 簡介
    • 市場統計
    • 作用和巨量資料的優點
    • 巨量資料相關經營者:成長推進因素·課題
    • 近幾年主要的發展
    • 主要企業

第8章 全球醫藥基因學市場:疾病類別

  • 市場區隔
  • 市場統計
  • 癌症·腫瘤
    • 主要的分析·統計
    • 市場統計
    • 癌症的類型
    • 藥物範例
    • 檢驗範例
    • 市場動態 & 主要企業
    • 近幾年主要的發展
  • 心血管疾病 (CVD)
    • 主要的分析·統計
    • 市場統計
    • 藥物範例
    • 檢驗範例
    • 近幾年主要的發展 & 主要企業
  • 中樞神經系統 (CNS)
    • 主要的分析·統計
    • 市場統計
    • 藥物範例
    • 檢驗範例
    • 近幾年主要的發展 & 主要企業
  • 感染疾病
    • 主要的分析·統計
    • 市場統計
    • 藥物範例
    • 近幾年主要的發展 & 主要企業
  • 其他
    • 主要的分析·統計
    • 市場統計
    • 藥物範例
    • 檢驗範例
    • 近幾年主要的發展 & 主要企業

第9章 地區分析

  • 各地區方案
  • 市場分析·統計
  • 北美
    • 市場範圍
    • 市場分析·統計
    • 市場動態
    • 主要的法律規章當局·相關團體
    • 美國
    • 加拿大
    • 近幾年主要的發展
  • 歐洲
    • 市場範圍
    • 市場分析·統計
    • 市場動態
    • 主要的法律規章當局·相關團體
    • 英國
    • 德國
    • 近幾年主要的發展
  • 亞太地區
    • 市場範圍
    • 市場分析·統計
    • 市場動態
    • 中國
    • 日本
    • 印度
    • 近幾年主要的發展
  • 其他地區
    • 市場分析·統計
    • 中東
    • 南美
    • 非洲
    • 近幾年的發展趨勢

第10章 企業簡介

  • ABBOTT LABORATORIES
  • AFFYMETRIX, INC.
  • ASSUREX HEALTH, INC.
  • ASTRAZENECA
  • ILLUMINA, INC.
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • MYRIAD GENETICS, INC.
  • PFIZER, INC.
  • QIAGEN, INC.
  • ROCHE HOLDING AG-BR
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERMO FISHER SCIENTIFIC
  • TRANSGENOMIC, INC.
  • 其他新興企業

第11章 用語

圖表

目錄
Product Code: MD09

Rapid advancement and innovation of new healthcare technologies such as next generation sequencing, High Throughput Screening (HTS), and Digital Polymerase Chain Reaction (PCR) are developing a strong base for the growth of Pharmacogenomics (PGx) market. The completion of first human genome project in 1990s has created a platform for the development of further enhanced Pharmacogenomics solutions. PGx is not a modernized market yet, however, the increasing demand for precision medicine, targeted therapeutics and increasing cases of adverse drug reactions are some of the major factors which led to a tremendous growth rate in the past few years.

Since the announcement of ‘Precision Medicine Initiative’ by the President Barack Obama in January 2015, a large number of Research and Development (R&D) programs has been taken up for the developing precise drugs, targeted therapeutics, and laboratory tests which required Pharmacogenomics analysis. At present, government initiatives are focused towards launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to fulfill the unmet needs of the patients. Most of the developments taking place in the present scenario are mainly related to oncology & cardiovascular diseases, but it is anticipated that it may target almost all therapeutic areas affected by genetic mutations.

Government regulations and standards are sustaining the growth and development of the PGx market. The main aim of these regulations is to make the PGx solutions more adaptable and focused toward oncology, pain management, central nervous system (CNS), Cardiovascular (CVD), and infectious diseases among others. The patients benefit indirectly from these regulations as it saves time and cuts down cost as the patients get the required treatment for the specific disease.

The market growth is propelled due to factors such as: rising usage in drug discovery processes, increasing demand for pharmacogenomics & precise drugs, technological innovation and advancement, increasing genetic disorder/abnormalities, and government support and regulations.

This study includes an overview and analysis of the PGx market, by type of ecosystem players ,type of therapeutics application, technology type, and geographical regions; allowing the researcher to develop a comprehensive outlook of the market. The PGx market report presents a detailed analysis of the key market dynamics and provides an extensive insight into various forms of developments, trends and key participants. All of the above mentioned report coverage parameters are discussed across different regions like North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, compliances, and regulatory bodies, and their involvement in the PGx market. The research incorporates Porter's Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it.

The answers to the following key questions can be found in the report:

  • What are the major market drivers, challenges and opportunities of the PGx market and their use cases?
  • What are the key trends and developments in the PGx market for genetic disease management?
  • What are the key developmental strategies in different therapeutics across all regions?
  • What are different types of PGx drugs and tests which are available in the market?
  • How will the key market players leverage on key developments such as Mergers and Acquisitions, Partnerships, and Product Launch among others?
  • Which geographical region will lead the global PGx market by the end of the forecast period?
  • Which different technologies are used to develop PGx solutions?
  • Who are the key players in the PGx market?
  • What are the government regulations for different PGx solutions?
  • What are different types of therapeutics in PGx market and which type of PGx product used in their treatment?
  • What is the different used case scenarios considered under different therapeutic applications?
  • What are the PGx market trends and key developments in different geographical regions?

The research deals with various aspects of the PGx market such as factors driving the market, its threats that can possibly slow down the market growth and the current growth opportunities that are going to shape the market expansion of PGx solutions. The research incorporates Porter's Five Forces Model for in-depth analysis of the PGx market and an assessment of the factors governing it. The report builds itself upon a comprehensive value chain giving a clear understanding of ecosystem of PGx market penetration.

Towards the end of the report, the readers will have a clear understanding of the market dynamics, major drivers and the underlying threats and challenges that the global PGx market is subjected to, including the estimation of the industry's growth in terms of production and revenue.

The report includes the profiles of major players in the PGx market that allows the readers to gain an insight into the various industry trends.

Some of the leading companies in the PGx market are listed below:

  • ABBOTT LABORATORIES
  • AFFYMETRIX, INC.
  • ASSUREX HEALTH, INC.
  • ASTRAZENECA
  • ILLUMINA, INC.
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • MYRIAD GENETICS, INC.
  • PFIZER, INC.
  • QIAGEN, INC.
  • ROCHE HOLDING AG-BR
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • THERMO FISHER SCIENTIFIC
  • TRANSGENOMIC, INC.

COUNTRIES COVERED

North America, Europe, Asia Pacific, Rest of the World.

Table of Contents

1. REPORT OVERVIEW

  • 1.1. REPORT SCOPE
    • 1.1.1. REPORT COVERAGE
    • 1.1.2. ASSUMPTIONS AND LIMITATIONS
    • 1.1.3. MARKET CLASSIFICATION & SEGMENTATION
  • 1.2. RESEARCH METHODOLOGY
    • 1.2.1. DATA POINTS CONSIDERED FOR MARKET SIZE ESTIMATION
    • 1.2.2. KEY DATA POINT SOURCES
      • 1.2.2.1. KEY DATA POINTS FROM PRIMARY SOURCES
      • 1.2.2.2. KEY DATA POINTS FROM SECONDARY SOURCES
    • 1.2.3. DATA TRIANGULATION
    • 1.2.4. TOP-DOWN APPROACH
    • 1.2.5. BOTTOM-UP APPROACH
  • 1.3. REPORT DESCRIPTION

2. EXECUTIVE SUMMARY

  • 2.1. GLOBAL MARKET SCENARIO

3. MARKET OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. PHARMACOGENOMICS: MECHANISM OF ACTION
  • 3.3. ROLE OF COMPANION DIAGNOSTICS IN PGX
  • 3.4. ROLE OF BIOMARKERS IN PGX
  • 3.5. ROLE OF MOLECULAR DIAGNOSTICS IN PGX
  • 3.6. BENEFITS OF PGX
  • 3.7. END-USE APPLICATIONS OF PGX
  • 3.8. MARKET DYNAMICS
    • 3.8.1. MARKET DRIVERS
    • 3.8.2. MARKET CHALLENGES
    • 3.8.3. MARKET OPPORTUNITIES

4. COMPETITIVE INSIGHTS

  • 4.1. KEY MARKET DEVELOPMENTS & STRATEGIES
    • 4.1.1. COMPETITIVE LANDSCAPE OF SOME OF THE KEY PLAYERS
    • 4.1.2. PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS
      • 4.1.2.1. KEY INSIGHTS
      • 4.1.2.2. RECENT PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS
    • 4.1.3. PRODUCT LAUNCH AND DEVELOPMENTS
      • 4.1.3.1. KEY INSIGHTS
      • 4.1.3.2. RECENT PRODUCT LAUNCH AND DEVELOPMENTS
    • 4.1.4. PATENTS, LICENSING, CERTIFICATION AND APPROVALS
      • 4.1.4.1. KEY INSIGHTS
      • 4.1.4.2. RECENT PATENTS, LICENSING, CERTIFICATION AND APPROVALS
    • 4.1.5. MERGERS AND ACQUISITIONS
      • 4.1.5.1. KEY INSIGHTS
      • 4.1.5.2. RECENT MERGERS AND ACQUISITIONS
    • 4.1.6. BUSINESS CONTRACTS AND BUSINESS EXPANSIONS
      • 4.1.6.1. KEY INSIGHTS
      • 4.1.6.2. RECENT BUSINESS CONTRACTS AND BUSINESS EXPANSIONS
    • 4.1.7. OTHER STRATEGIES
      • 4.1.7.1. KEY INSIGHTS
      • 4.1.7.2. RECENT DEVELOPMENTTS OF OTHER STRATEGIES
  • 4.2. PORTER'S FIVE FORCES ANALYSIS
    • 4.2.1. THREAT OF SUBSTITUTES
    • 4.2.2. THREAT OF NEW ENTRANTS
    • 4.2.3. BARGAINING POWER OF BUYERS
    • 4.2.4. BARGAINING POWER OF SUPPLIERS
    • 4.2.5. INTENSITY OF COMPETITIVE RIVALRY

5. INDUSTRY ANALYSIS

  • 5.1. PATENT ANALYSIS
    • 5.1.1. SOME OF THE KEY PLAYERS
    • 5.1.2. OTHERS (UNIVERSITY/HOSPITAL/PERSON)
  • 5.2. REGULATIONS, CONSORTIUMS, CERTIFICATIONS, & STANDARDS
    • 5.2.1. REGULATORY BODIES
    • 5.2.2. EXAMPLES OF SOME COMMON ACTS CERTIFICATIONS
  • 5.3. VALUE CHAIN ANALYSIS

6. GLOBAL PHARMACOGENOMICS MARKET BY TECHNOLOGY

  • 6.1. MARKET SEGMENTATION BY TECHNOLOGY
  • 6.2. MICROARRAY
    • 6.2.1. INTRODUCTION
    • 6.2.2. MICROARRAY: TYPES, APPLICATIONS & KEY PLAYERS
    • 6.2.3. MICROARRAY: MARKET DYNAMICS & RECENT DEVELOPMENTS
  • 6.3. SEQUENCING
    • 6.3.1. INTRODUCTION
    • 6.3.2. SEQUENCING: MARKET DYNAMICS, APPLICATIONS & KEY PLAYERS
    • 6.3.3. TYPES OF SEQUENCING TECHNOLOGIES
      • 6.3.3.1. SANGER SEQUENCING
      • 6.3.3.2. PYROSEQUENCING
      • 6.3.3.3. NEXT-GEN SEQUENCING (NGS)
        • 6.3.3.3.1. NEXT-GEN SEQUENCING (NGS) APPLICATIONS & KEY PLAYERS
        • 6.3.3.3.2. NEXT-GEN SEQUENCING (NGS) RECENT DEVELOPMENTS
  • 6.4. POLYMERASE CHAIN REACTION (PCR)
    • 6.4.1. INTRODUCTION
    • 6.4.2. PCR TYPES
    • 6.4.3. PCR: MARKET DYNAMICS, APPLICATIONS & KEY PLAYERS
  • 6.5. OTHER TECHNOLOGIES
    • 6.5.1. MASS SPECTROMETRY
    • 6.5.2. ELECTROPHORESIS

7. GLOBAL PHARMACOGENOMICS MARKET BY ECOSYSTEM PLAYERS

  • 7.1. PGX ECOSYSTEM PLAYERS: OVERVIEW
  • 7.2. MARKET SEGMENTATION BY ECOSYSTEM PLAYERS
    • 7.2.1. MARKET INSIGHTS & STATISTICS
  • 7.3. DIAGNOSTIC TEST COMPANIES
    • 7.3.1. INTRODUCTION
    • 7.3.2. MARKET STATISTICS
    • 7.3.3. DIAGNOSTIC COMPANIES: DRIVERS & CHALLENGES
    • 7.3.4. RECENT KEY DEVELOPMENTS
    • 7.3.5. KEY PLAYERS
  • 7.4. PHARMACEUTICALS COMPANIES
    • 7.4.1. INTRODUCTION
    • 7.4.2. MARKET STATISTICS
    • 7.4.3. DRUG DEVELOPMENT PROCESS
    • 7.4.4. ROLE OF PHARMACEUTICAL COMPANIES & EXAMPLE OF SOME DRUGS
    • 7.4.5. PHARMACEUTICALS COMPANIES: DRIVERS & CHALLENGES
    • 7.4.6. RECENT KEY DEVELOPMENTS
    • 7.4.7. KEY PLAYERS
  • 7.5. SERVICE PROVIDERS
    • 7.5.1. INTRODUCTION
    • 7.5.2. MARKET STATISTICS
    • 7.5.3. SERVICE PROVIDER: ROLES & BIG DATA BENEFITS
    • 7.5.4. BIG DATA COMPANIES: DRIVERS & CHALLENGES
    • 7.5.5. RECENT KEY DEVELOPMENTS
    • 7.5.6. KEY PLAYERS

8. GLOBAL PHARMACOGENOMICS MARKET BY THERAPEUTIC APPLICATIONS

  • 8.1. MARKET SEGMENTATION
  • 8.2. MARKET STATISTICS
  • 8.3. CANCER/ONCOLOGY
    • 8.3.1. KEY INSIGHTS & STATISTICS
    • 8.3.2. MARKET STATISTICS
    • 8.3.3. TYPES OF CANCER
    • 8.3.4. CANCER: EXAMPLES OF SOME DRUGS
    • 8.3.5. CANCER: EXAMPLES OF SOME TESTS
    • 8.3.6. MARKET DYNAMICS & KEY PLAYERS
    • 8.3.7. RECENT KEY DEVELOPMENTS
  • 8.4. CARDIOVASCULAR DISEASES (CVD)
    • 8.4.1. KEY INSIGHTS & STATISTICS
    • 8.4.2. MARKET STATISTICS
    • 8.4.3. CVD: EXAMPLES OF SOME DRUGS
    • 8.4.4. CVD: EXAMPLES OF SOME TESTS
    • 8.4.5. RECENT KEY DEVELOPMENTS & KEY PLAYERS
  • 8.5. CENTRAL NERVOUS SYSTEM (CNS)
    • 8.5.1. KEY INSIGHTS & STATISTICS
    • 8.5.2. MARKET STATISTICS
    • 8.5.3. CNS: EXAMPLES OF SOME DRUGS
    • 8.5.4. CNS: EXAMPLES OF SOME TESTS
    • 8.5.5. RECENT KEY DEVELOPMENTS & KEY PLAYERS
  • 8.6. INFECTIOUS DISEASES
    • 8.6.1. KEY INSIGHTS & STATISTICS
    • 8.6.2. MARKET STATISTICS
    • 8.6.3. INFECTIOUS DISEASES: EXAMPLES OF SOME DRUGS
    • 8.6.4. RECENT KEY DEVELOPMENTS & KEY PLAYERS
  • 8.7. OTHER DISEASES
    • 8.7.1. KEY INSIGHTS & STATISTICS
    • 8.7.2. MARKET STATISTICS
    • 8.7.3. OTHER DISEASES: EXAMPLES OF SOME DRUGS
    • 8.7.4. OTHER DISEASES: EXAMPLES OF SOME TESTS
    • 8.7.5. RECENT KEY DEVELOPMENTS & KEY PLAYERS

9. GLOBAL PHARMACOGENOMICS MARKET BY GEOGRAPHY

  • 9.1. GEOGRAPHICAL SCENARIO
  • 9.2. MARKET INSIGHTS & STATISTICS
  • 9.3. NORTH AMERICA
    • 9.3.1. MARKET SCOPE
    • 9.3.2. NORTH AMERICA: MARKET INSIGHTS & STATISTICS
    • 9.3.3. NORTH AMERICAN MARKET DYNAMICS
    • 9.3.4. KEY REGULATORY BODIES & ASSOCIATIONS
    • 9.3.5. THE U.S.
      • 9.3.5.1. THE U.S.: MARKET STATISTICS
      • 9.3.5.2. THE U.S.: KEY INSIGHTS
    • 9.3.6. CANADA
    • 9.3.7. RECENT KEY DEVELOPMENTS
  • 9.4. EUROPE
    • 9.4.1. MARKET SCOPE
    • 9.4.2. EUROPE: MARKET INSIGHTS & STATISTICS
    • 9.4.3. EUROPEAN MARKET DYNAMICS
    • 9.4.4. KEY REGULATORY BODIES & ASSOCIATIONS
    • 9.4.5. THE U.K.
    • 9.4.6. GERMANY
    • 9.4.7. RECENT KEY DEVELOPMENTS
  • 9.5. ASIA-PACIFIC (APAC)
    • 9.5.1. MARKET SCOPE
    • 9.5.2. APAC: MARKET INSIGHTS & STATISTICS
    • 9.5.3. APAC MARKET DYNAMICS
    • 9.5.4. CHINA
    • 9.5.5. JAPAN
    • 9.5.6. INDIA
    • 9.5.7. RECENT KEY DEVELOPMENTS
  • 9.6. REST OF THE WORLD (ROW)
    • 9.6.1. ROW: MARKET INSIGHTS & STATISTICS
    • 9.6.2. MIDDLE EAST
    • 9.6.3. SOUTH AMERICA
    • 9.6.4. AFRICA
    • 9.6.5. RECENT KEY DEVELOPMENT

10. COMPANY OVERVIEW

  • 10.1. ABBOTT LABORATORIES
    • 10.1.1. OVERVIEW
    • 10.1.2. FINANCIALS
    • 10.1.3. FINANCIAL SUMMARY
    • 10.1.4. KEY DEVELOPMENTS
    • 10.1.5. SWOT ANALYSIS
  • 10.2. AFFYMETRIX, INC.
    • 10.2.1. OVERVIEW
    • 10.2.2. FINANCIALS
    • 10.2.3. FINANCIAL SUMMARY
    • 10.2.4. KEY DEVELOPMENTS
    • 10.2.5. SWOT ANALYSIS
  • 10.3. ASSUREX HEALTH, INC.
    • 10.3.1. OVERVIEW
    • 10.3.2. KEY DEVELOPMENTS
    • 10.3.3. SWOT ANALYSIS
  • 10.4. ASTRAZENECA
    • 10.4.1. OVERVIEW
    • 10.4.2. FINANCIALS
    • 10.4.3. FINANCIAL SUMMARY
    • 10.4.4. KEY DEVELOPMENTS
    • 10.4.5. SWOT ANALYSIS
  • 10.5. ILLUMINA, INC.
    • 10.5.1. OVERVIEW
    • 10.5.2. FINANCIALS
    • 10.5.3. FINANCIAL SUMMARY
    • 10.5.4. KEY DEVELOPMENTS
    • 10.5.5. SWOT ANALYSIS
  • 10.6. LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 10.6.1. OVERVIEW
    • 10.6.2. FINANCIALS & FINANCIAL SUMMARY
    • 10.6.3. KEY DEVELOPMENTS
    • 10.6.4. SWOT ANALYSIS
  • 10.7. MYRIAD GENETICS, INC.
    • 10.7.1. OVERVIEW
    • 10.7.2. FINANCIALS & FINANCIAL SUMMARY
    • 10.7.3. KEY DEVELOPMENTS
    • 10.7.4. SWOT ANALYSIS
  • 10.8. PFIZER, INC.
    • 10.8.1. OVERVIEW
    • 10.8.2. FINANCIALS
    • 10.8.3. FINANCIAL SUMMARY
    • 10.8.4. KEY DEVELOPMENTS
    • 10.8.5. SWOT ANALYSIS
  • 10.9. QIAGEN, INC.
    • 10.9.1. OVERVIEW
    • 10.9.2. FINANCIALS
    • 10.9.3. FINANCIAL SUMMARY
    • 10.9.4. KEY DEVELOPMENTS
    • 10.9.5. SWOT ANALYSIS
  • 10.1O ROCHE HOLDING AG-BR
    • 10.10.1. OVERVIEW
    • 10.10.2. FINANCIALS
    • 10.10.3. FINANCIAL SUMMARY
    • 10.10.4. KEY DEVELOPMENTS
    • 10.10.5. SWOT ANALYSIS
  • 10.11. TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.11.1. OVERVIEW
    • 10.11.2. FINANCIALS
    • 10.11.3. FINANCIAL SUMMARY
    • 10.11.4. KEY DEVELOPMENTS
    • 10.11.5. SWOT ANALYSIS
  • 10.12. THERMO FISHER SCIENTIFIC
    • 10.12.1. OVERVIEW
    • 10.12.2. FINANCIALS
    • 10.12.3. FINANCIAL SUMMARY
    • 10.12.4. KEY DEVELOPMENTS
    • 10.12.5. SWOT ANALYSIS
  • 10.13. TRANSGENOMIC, INC.
    • 10.13.1. OVERVIEW
    • 10.13.2. FINANCIALS & FINANCIAL SUMMARY
    • 10.13.3. KEY DEVELOPMENTS
    • 10.13.4. SWOT ANALYSIS
  • 10.14. OTHER EMERGING COMPANIES
    • 10.14.1. DIAGNOSTIC TEST COMPANIES
      • 10.14.1.1. COMPANIONDX REFERENCE LAB, LLC
      • 10.14.1.2. MAPMY GENOME
      • 10.14.1.3. ASURAGEN
      • 10.14.1.4. 23ANDME
      • 10.14.1.5. CNSDOSE
    • 10.14.2. PHARMACEUTICAL COMPANIES
      • 10.14.2.1. ACTINIUM PHARMACEUTICALS, INC
      • 10.14.2.2. FOUNDATION MEDICINE
    • 10.14.3. SERVICE PROVIDERS
      • 10.14.3.1. PGX SOFTWARE LLC
      • 10.14.3.2. GENE LOGIC
      • 10.14.3.3. GENEWIZ
      • 10.14.3.4. CONATUS CONSULTING, LLC
    • 10.14.4. CARE PROVIDERS
      • 10.14.4.1. GENE DX
      • 10.14.4.2. MAYO CLINIC

11. LIST OF ACRONYMS

LIST OF FIGURES

  • YEAR CONSIDERATION
  • MARKET CLASSIFICATION & SEGMENTATION
  • RESEARCH METHODOLOGY
  • GLOBAL PHARMACOGENOMICS MARKET ($BILLION)
  • GLOBAL PHARMACOGENOMICS MARKET VALUE, 2015-2022 ($BILLION)
  • GLOBAL PGX MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • GLOBAL PGX MARKET SHARE, BY THERAPEUTIC APPLICATION, 2015-2022 ($BILLION)
  • GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY-2022
  • MECHANISM OF ACTION
  • ROLE OF COMPANION DIAGNOSTICS IN PGX
  • ROLE OF BIOMAKERS IN PGX
  • ROLE OF MOLECULAR DIAGNOSTICS IN PGX
  • BENEFITS OF PGX
  • END-USE APPLICATIONS OF PGX
  • MARKET DYNAMICS
  • PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS: KEY PLAYERS ANALYSIS
  • PRODUCT LAUNCH AND DEVELOPMENTS: KEY PLAYERS ANALYSIS
  • PATENTS, LICENSING, CERTIFICATION AND APPROVALS: KEY PLAYERS ANALYSIS
  • MERGERS AND ACQUISITIONS: KEY PLAYERS ANALYSIS
  • BUSINESS CONTRACTS AND BUSINESS EXPANSIONS: KEY PLAYERS ANALYSIS
  • OTHERS STRATEGIES: KEY PLAYERS ANALYSIS
  • PORTER'S FIVE FORCES ANALYSIS
  • THREAT OF SUBSTITUTES
  • THREAT OF NEW ENTRANTS
  • BARGAINING POWER OF BUYERS
  • BARGAINING POWER OF SUPPLIERS
  • INTENSITY OF COMPETITIVE RIVALRY
  • ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS
  • ROLE OF FDA IN PGX
  • CLASSIFICATION OF MEDICAL DEVICES
  • EXAMPLES OF SOME COMMON ACTS
  • EXAMPLE OF SOME CERTIFICATIONS
  • VALUE CHAIN ANALYSIS
  • EXAMPLE OF SOME SIGNIFICANT PLAYERS IN PGX VALUE CHAIN
  • GENERALIZED PROCESS FOR THE MICROARRAY
  • DIFFERENT TYPES OF MICROARRAYS
  • APPLICATIONS OF MICROARRAYS
  • MICROARRAY- DRIVERS & CHALLENGES
  • SEQUENCING TECHNOLOGIES IN PGX
  • SEQUENCING - DRIVERS & CHALLENGES
  • APPLICATIONS OF SEQUENCING
  • NGS- DRIVERS & CHALLENGES
  • APPLICATIONS OF NGS
  • GENERALIZED PROCESS FOR PCR
  • DIFFERENT TYPES OF PCR
  • PCR - DRIVERS & CHALLENGES
  • APPLICATIONS OF PCR
  • APPLICATIONS OF MASS SPECTROMETRY
  • APPLICATIONS OF ELECTROPHORESIS
  • OVERVIEW OF PGX ECOSYSTEM PLAYERS
  • GLOBAL PGX MARKET BY ECOSYSTEM PLAYERS
  • GLOBAL PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • GLOBAL PGX ECOSYSTEM MARKET, BY DIAGNOSTIC TESTS COMPANIES, 2015-2022 ($BILLION)
  • GLOBAL PGX DIAGNOSTIC TESTS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)
  • GLOBAL PGX DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • DIAGNOSTIC COMPANIES- DRIVERS & CHALLENGES
  • GLOBAL PGX ECOSYSTEM MARKET, BY PHARMACEUTICAL COMPANIES, 2015-2022 ($BILLION)
  • GLOBAL PGX PHARMACEUTICAL MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)
  • GLOBAL PGX PHARMACEUTICAL MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • DRUG DEVELOPMENT PROCESS
  • ROLE OF PHARMACEUTICALS COMPANIES
  • PHARMACEUTICALS COMPANIES- DRIVERS & CHALLENGES
  • GLOBAL PGX ECOSYSTEM MARKET, BY SERVICE PROVIDERS, 2015-2022 ($BILLION)
  • GLOBAL PGX SERVICE PROVIDERS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)
  • GLOBAL PGX SERVICE PROVIDERS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • THREE DATA DRIVERS OF PGX MARKET
  • BENEFITS OF BIG DATA
  • BIG DATA COMPANIES- DRIVERS & CHALLENGES
  • GLOBAL PGX MARKET BY THERAPEUTICS APPLICATIONS
  • GLOBAL PGX MARKET, BY THERAEUTICS APPLICATION, 2015-2022 ($BILLION)
  • GLOBAL PGX MARKET BY ONCOLOGY, 2015-2022($BILLION)
  • GLOBAL PGX ONCOLOGY MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • GLOBAL PGX ONCOLOGY MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • TYPES OF CANCER
  • ONCOLOGY MARKET DYNAMICS
  • GLOBAL PGX MARKET BY CVD, 2015-2022 ($BILLION)
  • GLOBAL PGX CVD MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • GLOBAL PGX CVD MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • GLOBAL PGX MARKET BY CNS, 2015-2022 ($BILLION)
  • GLOBAL PGX CNS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • GLOBAL PGX CNS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • GLOBAL PGX MARKET BY INFECTIOUS DISEASES, 2015-2022 ($BILLION)
  • GLOBAL PGX INFECTIOUS DISEASES MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • GLOBAL PGX INFECTIOUS DISEASES MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • GLOBAL PGX MARKET BY OTHER DISEASES, 2015-2022 ($BILLION)
  • GLOBAL PGX OTHER DISEASES MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • GLOBAL PGX OTHER DISEASES MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • GROWTH TRAJECTORY OF PGX MARKET
  • GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY, 2015-2022 ($BILLION)
  • GLOBAL PHARMACOGENOMICS MARKET, BY GEOGRAPHY (2015)
  • NORTH AMERICAN PGX MARKET, 2015
  • NORTH AMERICAN PGX MARKET, 2015-2022 ($BILLION)
  • NORTH AMERICAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION)
  • NORTH AMERICAN PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • NORTH AMERICAN PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)
  • NORTH AMERICAN MARKET DYNAMICS
  • KEY REGULATORY BODIES & ASSOCIATIONS
  • THE U.S. PGX MARKET, 2015-2022 ($BILLION)
  • THE U.S. PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • THE U.S. PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)
  • CANADA PGX MARKET DYNAMICS
  • EUROPEAN PGX MARKET, 2015
  • EUROPEAN PGX MARKET, 2015-2022($BILLION)
  • EUROPEAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION)
  • EUROPEAN PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • EUROPEAN PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)
  • EUROPEAN MARKET DYNAMICS
  • KEY REGULATORY BODIES & ASSOCIATIONS
  • THE U.K. PGX MARKET, 2015-2022 ($BILLION)
  • THE GERMANY PGX MARKET, 2015-2022 ($BILLION)
  • APAC COUNTRY-WISE CAGR OF PGX MARKET
  • APAC PGX MARKET, 2015-2022 ($BILLION)
  • APAC PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION)
  • APAC PHARMACOGENOMICS MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • APAC PHARMACOGENOMICS MARKET, BY THERAPEUTIC APPLICATIONS, 2015-2022 ($BILLION)
  • APAC MARKET DYNAMICS
  • THE CHINA PGX MARKET, 2015-2022 ($BILLION)
  • CHINA MARKET DYNAMICS
  • THE JAPAN PGX MARKET, 2015-2022 ($BILLION)
  • THE INDIAN PGX MARKET, 2015-2022 ($BILLION)
  • INDIAN MARKET DYNAMICS
  • REGION-WISE CAGR OF PGX MARKET
  • ROW PGX MARKET, 2015-2022 ($BILLION)
  • ROW PGX MARKET, BY SUB-REGION, 2015-2022 ($BILLION)
  • ROW PGX MARKET, BY ECOSYSTEM, 2015-2022 ($BILLION)
  • ROW PGX MARKET, BY THERAPEUTICS, 2015-2022 ($BILLION)
  • MIDDLE EAST PGX MARKET, 2015-2022 ($BILLION)
  • SOUTH AMERICAN PGX MARKET, 2015-2022 ($BILLION)
  • AFRICAN PGX MARKET, 2015-2022 ($BILLION)
  • ABBOTT LABORATORIES, INC. - OVERALL FINANCIALS, 2013-2015 ($BILLION)
  • ABBOTT LABORATORIES, INC. - FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION)
  • ABBOTT LABORATORIES, INC. - FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION)
  • ABBOTT LABORATORIES, INC. - SWOT ANALYSIS
  • AFFYMETRIX, INC. - OVERALL FINANCIALS, 2013-2015 ($MILLION)
  • AFFYMETRIX, INC. - FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION)
  • AFFYMETRIX, INC. - FINANCIALS BY GEOGRAPHY, 2013-2015 ($MILLION)
  • AFFYMETRIX, INC. - SWOT ANALYSIS
  • ASSUREX HEALTH, INC. - SWOT ANALYSIS
  • ASTRAZENECA - OVERALL FINANCIALS, 2013-2015 ($BILLION)
  • ASTRAZENECA- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION)
  • ASTRAZENECA- FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION)
  • ASTRAZENECA- SWOT ANALYSIS
  • ILLUMINA, INC. - OVERALL FINANCIALS, 2013-2015 ($MILLION)
  • ILLUMINA, INC. - FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION)
  • ILLUMINA, INC. - FINANCIALS BY GEOGRAPHY, 2013-2015 ($MILLION)
  • ILLUMINA, INC. - SWOT ANALYSIS
  • LABORATORY CORPORATION OF AMERICA HOLDING. - OVERALL FINANCIALS, 2013-2015 ($MILLION)
  • LABORATORY CORPORATION OF AMERICA HOLDING-FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($ MILLION)
  • LABORATORY CORPORATION OF AMERICA HOLDING. - SWOT ANALYSIS
  • MYRIAD GENETICS, INC. - OVERALL FINANCIALS, 2013-2015 ($MILLION)
  • MYRIAD GENETICS, INC. - FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION)
  • MYRIAD GENETICS, INC. - SWOT ANALYSIS
  • PFIZER, INC. - OVERALL FINANCIALS, 2013-2015 ($BILLION)
  • PFIZER, INC. - FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION)
  • PFIZER, INC. - FINANCIALS BY BUSINESS SEGMENTS, 2014-2015 ($BILLION)
  • PFIZER, INC. - FINANCIALS BY BUSINESS SEGMENT, 2013
  • PFIZER, INC. - SWOT ANALYSIS
  • QIAGEN- OVERALL FINANCIALS, 2013-2015 ($MILLION)
  • QIAGEN- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($MILLION)
  • QIAGEN- FINANCIALS BY GEOGRAPHY, 2013-2015 ($MILLION)
  • QIAGEN- SWOT ANALYSIS
  • ROCHE HOLDING- OVERALL FINANCIALS, 2013-2015 ($BILLION)
  • ROCHE HOLDING- FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION)
  • ROCHE HOLDING- FINANCIALS OF DIAGNOSTICS DIVISION BY GEOGRAPHY, 2013-2015 ($BILLION)
  • ROCHE HOLDING- FINANCIALS OF PHARMACEUTICALS, SEGMENT BY GEOGRAPHY, 2013-2015 ($BILLION)
  • ROCHE HOLDING- SWOT ANALYSIS
  • TEVA PHARMACEUTICAL LTD. - OVERALL FINANCIALS, 2013-2015 ($BILLION)
  • TEVA PHARMACEUTICAL LTD. - FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION)
  • TEVA PHARMACEUTICAL LTD. - FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD. - SWOT ANALYSIS
  • THERMO FISHER, INC. - OVERALL FINANCIALS, 2013-2015 ($BILLION)
  • THERMO FISHER, INC. - FINANCIALS BY BUSINESS SEGMENTS, 2013-2015 ($BILLION)
  • THERMO FISHER, INC. - FINANCIALS BY GEOGRAPHY, 2013-2015 ($BILLION)
  • THERMO FISHER SCIENTIFIC, INC. - SWOT ANALYSIS
  • TRANSGENOMIC, INC. - OVERALL FINANCIALS, 2013-2015 ($MILLION)
  • TRANSGENOMIC, INC. - FINANCIALS BY BUSINESS SEGEMENTS, 2013-2015 ($MILLION)
  • TRANSGENOMIC, INC. - SWOT ANALYSIS

LIST OF TABLES

  • COMPETITIVE LANDSCAPE: SOME OF THE KEY PLAYERS
  • RECENT PARTNERSHIPS, JOINT VENTURES AND COLLABORATIONS
  • RECENT PRODUCT LAUNCH AND DEVELOPMENTS
  • RECENT PATENTS, LICENSING, CERTIFICATION AND APPROVALS
  • RECENT MERGERS AND ACQUISITIONS
  • RECENT BUSINESS CONTRACTS AND BUSINESS EXPANSIONS
  • RECENT DEVELOPMENTTS OF OTHER STRATEGIES
  • PATENT ANALYSIS OF SOME KEY PLAYERS
  • PATENT ANALYSIS OF SOME UNIVERSITY/HOSPITAL/PERSON
  • MICROARRAY- RECENT KEY DEVELOPMENTS
  • NGS- RECENT KEY DEVELOPMENTS
  • DIFFERENCE BETWEEN REALT TIME & DIGITAL PCR
  • DIAGNOSTIC TEST COMPANIES- RECENT KEY DEVELOPMENTS
  • EXAMPLE OF SOME PHARMACOGENOMIC DRUGS
  • PHARMACEUTICALS COMPANIES- RECENT KEY DEVELOPMENTS
  • SERVICE PROVIDERS- RECENT KEY DEVELOPMENTS
  • CANCER- EXAMPLES OF SOME DRUGS
  • CANCER- EXAMPLES OF SOME TESTS
  • ONCOLOGY- RECENT KEY DEVELOPMENTS
  • CVD- EXAMPLES OF SOME DRUGS
  • CVD- EXAMPLES OF SOME TESTS
  • CNS- EXAMPLES OF SOME DRUGS
  • CNS- EXAMPLES OF SOME TESTS
  • INFECTIOUS DISEASES- EXAMPLES OF SOME DRUGS
  • OTHER DISEASES- EXAMPLES OF SOME DRUGS
  • NORTH AMERICAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION)
  • NORTH AMERICAN PHARMACOGENOMICS MARKET RECENT KEY DVELOPMENTS
  • EUROPEAN PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION)
  • EUROPEAN PGX MARKET RECENT KEY DEVELOPMENTS
  • APAC PHARMACOGENOMICS MARKET, BY COUNTRY WISE, 2015-2022 ($BILLION)
  • APAC PHARMACOGENOMICS MARKET RECENT KEY DEVELOPMENTS
  • ROW PHARMACOGENOMICS MARKET, BY SUB-REGION, 2015-2022
  • ROW RECENT KEY DEVELOPMENT
  • ABBOTT LABORATORIES, INC. RECENT DEVELOPMENTS
  • AFFYMETRIX, INC. RECENT DEVELOPMENTS
  • ASSUREX HEALTH, INC. RECENT DEVELOPMENTS
  • ASTRAZENECA RECENT DEVELOPMENTS
  • ILLUMINA, INC. RECENT DEVELOPMENTS
  • LABORATORY CORPORATION OF AMERICA HOLDING RECENT DEVELOPMENTS
  • MYRIAD GENETICS RECENT DEVELOPMENTS
  • PFIZER, INC. RECENT DEVELOPMENTS
  • QIAGEN RECENT DEVELOPMENTS
  • ROCHE HOLDING RECENT DEVELOPMENTS
  • TEVA PHARMACEUTICAL INDUSTRIES LTD. RECENT DEVELOPMENTS
  • THERMO FISHER, INC. RECENT DEVELOPMENTS
  • TRANSGENOMIC, INC. RECENT DEVELOPMENTS
Back to Top